Mochida Pharmaceutical (4534)

Tokyo
Currency in JPY
3,275.0
+25.0(+0.77%)
Closed
4534 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3,245.03,340.0
52 wk Range
2,863.03,625.0
Key Statistics
Edit
Bid/Ask
3,275.00 / 3,305.00
Prev. Close
3,250
Open
3,295
Day's Range
3,245-3,340
52 wk Range
2,863-3,625
Volume
15.5K
Average Volume (3m)
23.68K
1-Year Change
-1.5%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4534 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with low price volatility
Show more

Mochida Pharmaceutical Company Profile

Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. The company offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology. It offers Lialda for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Lexapro, an antidepressant drug; Epadel drug for hyperlipidemia and arteriosclerosis obliterans; Urece for the treatment of gout and hyperuricemia; and Treprost for the treatment of pulmonary arterial hypertension. In addition, the company provides Atelec to treat calcium channel blocker with a long-acting hypotensive effect; Tramcet, an analgesic for chronic pain and pain after tooth extraction; Heparin Sodium MOCHIDA, an anticoagulant agent; Beselna, a therapeutic agent for condyloma acuminatum and actinic keratosis; and Dinagest, a therapeutic agent for endometriosis, adenomyosis, and dysmenorrhea. Further it offers skin care, baby care, personal care, and nursing products. Additionally, the company develops mesalazine, ethyl icosapentate, daridorexant, dotinurad, and treprostinil drugs for the treatment of ulcerative colitis, hypertriglyceridemia, insomnia, gout and hyperuricemia, and pulmonary hypertension associated with interstitial lung disease; and dMD-001, a medical device that is used for the treatment of articular cartilage lesions, as well as dMD-002, which is used for the treatment of cavernous nerve injury. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Employees
1522
Market
Japan

Compare 4534 to Peers and Sector

Metrics to compare
4534
Peers
Sector
Relationship
P/E Ratio
25.6x11.7x−0.6x
PEG Ratio
−1.590.040.00
Price/Book
0.9x1.0x2.6x
Price / LTM Sales
1.1x1.5x3.1x
Upside (Analyst Target)
−2.3%15.6%53.0%
Fair Value Upside
Unlock28.3%8.0%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 127.78
Dividend Yield
2.44%
Industry Median 2.28%
Annualised payout
80
Paid unevenly
5-Years Growth
-1.21%
Growth Streak

Earnings

Latest Release
Nov 01, 2024
EPS / Forecast
35.86 / --
Revenue / Forecast
25.69B / 25.053B
EPS Revisions
Last 90 days

FAQ

What Is the Mochida Pharmaceutical (4534) Stock Price Today?

The Mochida Pharmaceutical stock price today is 3,275.00

What Stock Exchange Does Mochida Pharmaceutical Trade On?

Mochida Pharmaceutical is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for Mochida Pharmaceutical?

The stock symbol for Mochida Pharmaceutical is "4534."

Does Mochida Pharmaceutical Pay Dividends? What’s The Current Dividend Yield?

The Mochida Pharmaceutical dividend yield is 2.44%.

What Is the Mochida Pharmaceutical Market Cap?

As of today, Mochida Pharmaceutical market cap is 116.10B.

What is Mochida Pharmaceutical Earnings Per Share?

The Mochida Pharmaceutical EPS is 127.78.

What Is the Next Mochida Pharmaceutical Earnings Date?

Mochida Pharmaceutical will release its next earnings report on 06 Feb 2025.

From a Technical Analysis Perspective, Is 4534 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.